An EpiPen epinephrine auto-injector is shown in Hendersonville, Texas on October 10, 2013. THE CANADIAN PRESS/AP, Mark Zaleski

Opposition parties blast minister for ‘dangerous’ EpiPen shortage

The NDP says the Liberals must take all steps necessary to prevent a future supply crunch.

The federal opposition parties called on the Trudeau government Wednesday to urgently address the shortage of life-saving epinephrine auto-injectors, known as EpiPens.

But the Conservatives and New Democrats differ as to how to ensure an adequate supply.

The NDP says the Liberals must take all steps necessary to prevent a future supply crunch, even if it means threatening the drug maker with the loss of its patent on the device.

The Conservatives, on the other hand, recommended the government encourage development of a Canadian-based supply chain.

Drug giant Pfizer said this week that the EpiPens it produces are in short supply, with the potential that adult doses may not be available at all in August, a peak month for people who rely on the injectors to treat serious allergic reactions.

“Many Canadians rely on EpiPens as life-saving devices,” said NDP health critic Don Davies.

“The minister of health should never have allowed this dangerous situation to develop, and now it’s on her to fix this immediately.”

The government said it was doing everything in its power to resolve the shortage as soon as possible, and advised Canadians with allergies to keep expired products.

“We continue to work closely with Pfizer Canada,” said Thierry Belair, a spokesman for Health Minister Ginette Petitpas Taylor.

Related: Canada could run out of EpiPens by end of August

Government officials noted that four other companies — Kaleo Pharma, Taro Pharmaceuticals, Valeant Canada and Lincoln Medical — have been approved to sell their epinephrine auto-injector products in Canada, but that Health Canada can’t compel a private company to market and supply product.

Critics warn the shortages could continue to happen because there is no firm requirement that manufacturers provide a consistent supply.

Hematologist and medical historian Jacalyn Duffin thinks the government should designate a list of “essential” medicines and also foster a homegrown manufacturing industry, particularly since most drugs sold in Canada are made elsewhere.

EpiPens are just one of dozens of medications in short supply, said Duffin, who tracks drug shortages on her website, CanadianDrugShortage.com.

U.S.-based Pfizer produces EpiPens at a facility near St. Louis, Missouri, and there are no alternatives sold in Canada.

Health Canada said anyone who has an anaphylactic reaction but has only an expired EpiPen should use the expired product and immediately call 911.

Davies called that response to the shortage “unacceptable.

“Health Canada must ensure that they are always available in sufficient supply. People’s health and their lives are on the line.”

The New Democrats called on the agency to make it a requirement for patent holders to supply the drug or lose their authorization to sell into the Canadian market.

“When foreign drug companies fail to supply Canadians with life-saving pharmaceuticals, the federal government can and must take action, including expropriating patents if necessary,” said Davies.

But such an approach would lead to an even more critical shortage, or no supply at all, said Conservative health critic Marilyn Gladu, who noted there have been significant supply crunches for EpiPens in Canada three times in the past 12 months.

“That would put us in an even worse position,” said Gladu.

Instead, the Trudeau government needs to set the conditions necessary to encourage Pfizer or other drug makers to set up production facilities in Canada, she said.

Pfizer also announced in April that it was running out of EpiPens, blaming the shortage on manufacturing delays. The shortage was felt at that time in the United Kingdom, but not the United States.

Gladu said pricing may be a factor driving Pfizer’s product distributors in determining where scarce supplies should be shipped.

EpiPens can cost around $300 in the U.S., although drug chains including CVS sell generic versions for less, while in Canada they are priced at around $100. They are sold for even less in the U.K.

Terry Pedwell, The Canadian Press

Like us on Facebook and follow us on Twitter.

Just Posted

Rio Tinto donates $50K for Shames Mountain chairlift upgrades

The money was used to purchase the chairlift’s bull wheel replacement last summer

Broken axle caused New Hazelton train derailment: TSB

It could happen again without a different way to inspect trains

Cullen remains uncertain about political future

Says he’ll make decision in early March

Spring fishery closures mulled for south coast

Fewer fish are returning to rivers and more conservation needed, say feds

Terrace resident’s bill banning single-use plastics introduced in Ottawa

MP Nathan Cullen’s presented Ben Korving’s private member’s bill Wednesday

National Energy Board approves Trans Mountain pipeline again

Next step includes cabinet voting on the controversial expansion

B.C. Special Olympics officially underway in Vernon

Athlete’s Oath: “Let me win. But if I cannot win, let me be brave in the attempt.”

Vancouver Aquarium wants your help to name a baby killer whale

The public helped name Springer’s first calf, Spirit, and is being asked to help with the second

Guards protest firing of fellow officers charged with assault at B.C. prison

Corrections officers demonstrated in Maple Ridge on Friday afternoon

Skier dies at Revelstoke Mountain Resort

Cause of death for young man has not been released

R. Kelly charged with 10 counts of sexual abuse

R&B star has been accused of sexual misconduct involving women and underage girls for years

More sailings coming to 10 BC Ferries’ routes

Transportation Minister Claire Trevena said the sailings were originally cut in 2014

Cryptocurrency exchange CEO who suddenly died leaves Kelowna house in will

Gerald Cotten, holding the keys to money tied up in his virtual currency exchange, died in December.

Regulator’s report, coming today, unlikely to settle Trans Mountain pipeline battle

The Trans Mountain pipeline will remain a controversial topic both in the political ring and out

Most Read